Clinical Trials Browser

Phase 2/3 × OTHER × Neoadjuvant Therapy × Clear all

NCT04669496 2025-09-04

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Phase 2/3 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT07134218 2025-08-21

Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT06769919 2025-01-10

A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT03623737 2022-06-07

Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

Phase 2/3 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04968002 2021-07-20

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2/3 Withdrawn

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04025437 2019-09-04

Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02584556 2019-06-04

Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma

Phase 2/3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT01458717 2018-05-02

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

Phase 2/3 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms, Recurrence